Related Experiment Video
Updated: Feb 18, 2026

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
Polyphenols Treatment in Patients with Nonalcoholic Fatty Liver Disease
Ludovico Abenavoli1, Natasa Milic2, Francesco Luzza1
1Department of Health Sciences, University Magna Græcia, Campus Germaneto, Viale Europa, 88100, Catanzaro, Italy.
Abstract:
Nonalcoholic fatty liver disease (NAFLD) affects 25-30% of the general population worldwide and this high prevalence is linked with lifestyle and dietetic changes, not only in Western countries, but also in the urban areas of developing countries. Several pharmacological approaches were proposed in the treatment of NAFLD, but the reported results are inconclusive. International guidelines recommended the reduction of dietary fat and fructose, in association with some physical activity. In this context, it was reported that the protective effects of traditional Mediterranean diet, related to the high concentration of antioxidant compounds, particularly of polyphenols. Polyphenols are a heterogeneous class of plant derived compounds, with some proven hepatoprotective effects. Our opinion is that the adherence to traditional Mediterranean diet characterized by the consumption of antioxidant-rich foods in general and of polyphenols in particular, can be considered as a potential new approach in the treatment of NAFLD.
More Related Videos
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
08:20Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model
Published on: December 2, 2022
Related Concept Videos
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Atherosclerosis III: Management
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Chronic Pancreatitis II: Collaborative Care
Assessment: